← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › CD20 (Clusters of Differentiation 20) inhibitors
ofatumumab
L01FA02
Forms & Strengths
- Subcutaneous injection: 20 mg/0.4 mL in a pre-filled auto-injector (Sensoready pen)
Adult Dosing
- Relapsing multiple sclerosis: 20 mg subcutaneously at Weeks 0, 1, and 2, followed by 20 mg monthly starting at Week 4
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults
Mechanism of Action
- Anti-CD20 monoclonal antibody that binds to the CD20 molecule on B-lymphocytes, inducing cell lysis and depletion of B-cells
Contraindications
- Active hepatitis B virus infection
- Known hypersensitivity to ofatumumab or any of its excipients
Adverse Reactions
- Injection-site reactions (pain, swelling, erythema)
- Upper respiratory tract infections
- Headache
- Systemic injection-related reactions (fever, headache, myalgia, chills, fatigue)
- Urinary tract infections
- Decreased immunoglobulin levels
Drug Interactions
- Immunosuppressive therapies (increased risk of immunosuppression when used concurrently)
- Live, live-attenuated, or BCG vaccines (vaccination is not recommended during treatment and after discontinuation until B-cell recovery)
Curated Content: Needs Vetting Before Put to Clinical Use